Latus Bio secured a new $97 million Series A to advance an AAV capsid-variant platform, funding initial clinical progress for its Huntington’s disease and late-infantile CLN2 programs. The financing is designed to carry operations through milestones including initial clinical data for LTS-201 and LTS-101. In parallel, coverage of the company’s earlier fundraising indicated it has raised additional capital to start its first clinical trials. The new round positions Latus to build clinical momentum and potentially sidestep delivery and dosing issues that have weighed on other late-stage gene therapy contenders. As AAV vector competition intensifies, the core differentiator remains capsid engineering that can expand therapeutic breadth while maintaining safety and scalable manufacturing.